Cancer Insurance Denied in Taiwan: Appeal Guide

Cancer is the leading cause of death in Taiwan, and the insurance industry has developed a wide range of cancer-specific products to complement NHI coverage. Yet cancer insurance denials in Taiwan are among the most common and contentious. Whether the denial is from NHI refusing to cover a new cancer drug or from a private insurer disputing whether your diagnosis meets their CI rider definition, here is how to fight back.

Cancer Coverage Under NHI

NHI provides comprehensive cancer coverage in Taiwan, including:

• Surgery, chemotherapy, and radiotherapy
• Standard cancer drugs on the NHI formulary
• Hospitalization during cancer treatment
• Palliative care

Where NHI falls short:

• Newer targeted therapies and immunotherapies may not be on the NHI formulary
• Proton beam therapy is not covered (or has limited coverage) for most cancer types
• CAR-T cell therapy and some gene therapies are not yet NHI-covered
• Certain imported drugs, even if clinically superior, may require special approval or be self-pay

For NHI gaps, patients in Taiwan either pay out of pocket or rely on private supplemental insurance.

Private Cancer Insurance in Taiwan: Product Types

Cancer-specific riders (癌症險): The most common type. Pays defined benefits upon cancer diagnosis and during treatment. Typical benefits include:

• Initial diagnosis benefit (初次罹癌保險金)
• In-patient daily benefit during cancer treatment (癌症住院日額)
• Surgery benefit
• Chemotherapy/radiotherapy benefit
• Bone marrow transplant benefit

Critical illness lump sum (重大疾病險): Pays a single lump sum when cancer is diagnosed. The entire sum insured is paid at once — useful for funding treatment costs that NHI does not cover.

Major illness and injury rider (重大傷病險): Triggered by the NHI issuing a major illness and injury card (重大傷病卡) for your condition. Taiwan's NHI major illness list includes most cancers.

Common Denial Reasons for Cancer Insurance Claims

In situ cancer not covered. Many older cancer rider policies in Taiwan exclude carcinoma in situ (原位癌) from the main initial diagnosis benefit, treating it as a lesser cancer requiring a smaller or separate benefit. If you are diagnosed with an in situ carcinoma, verify whether your rider includes a specific in situ benefit or excludes it entirely.

Cancer type excluded by name. Certain cancers are often excluded or given reduced benefits in older policies: skin cancers other than malignant melanoma, thyroid cancer at early stage, prostate cancer at low risk scores. Review your specific exclusion list.

Waiting period violation. Cancer riders typically impose a 30–90 day waiting period. A diagnosis confirmed during this period will be excluded. If you believe you were already developing cancer before the policy and simply received the diagnosis shortly after starting coverage, the exclusion still applies — the diagnosis date controls, not the onset date.

Staging dispute. Some CI and cancer rider policies pay different amounts based on cancer stage. An insurer may argue the cancer was caught at a lower stage than your oncologist's staging report indicates. This is uncommon but does occur.

Major illness card not yet issued. For 重大傷病 riders, if NHIA has not yet issued your card — because the application is pending — the rider benefit cannot yet be triggered. The dispute here is with NHIA's issuance timeline, not directly with the insurer.

Non-disclosure at underwriting. If you had prior cancer or cancer treatment that was not disclosed on your application, the insurer may deny the claim. A recurrence of a disclosed prior cancer triggers the declared exclusion. Undisclosed prior cancer may trigger a non-disclosure defense.

Drug or treatment not covered under cancer rider. Cancer riders define specific covered treatments. If your cancer is being treated with a combination therapy that includes a drug not listed in the rider's benefit schedule, that component may be denied.

How to Appeal

Step 1: Obtain Comprehensive Cancer Documentation

Assemble the complete medical picture:

• Diagnosis certificate (診斷書) from your oncologist
• Pathology report confirming histological type, grade, and stage
• Treatment plan from your oncologist
• Records showing treatment dates and types

Step 2: Review Your Rider Terms

Locate the specific benefit clauses and exclusions in your cancer rider. If the insurer is citing an exclusion, verify the exact wording. Policy language is sometimes ambiguous — ambiguity generally favors the policyholder under Taiwan contract law.

Step 3: Formal Internal Appeal

Submit a written appeal to your insurer. Include all medical documentation and a specific rebuttal of each denial reason. If an oncologist's opinion is needed to support that your diagnosis meets the rider definition, attach it.

Step 4: Financial Ombudsman Institution (FOI)

Cancer rider definition disputes are among the most frequently mediated cases at the FOI (foi.org.tw). The FOI is free, accessible, and has resolved many cases in policyholders' favor where insurers applied overly narrow definitions. File within 2 years of the insurer's decision (check current FOI rules for the exact deadline).

Step 5: FSC and Civil Courts

For systemic issues, file with the FSC at fsc.gov.tw. For high-value disputes the FOI cannot resolve, consider civil litigation.

Key Advice

If you hold an older cancer rider purchased 10–20 years ago, the definitions may be significantly narrower than current market standards. Check whether your insurer has offered a rider upgrade — some insurers proactively offer updated terms. If not, understanding the older definitions precisely is essential to your appeal strategy.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word. Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal